<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098365</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1567824</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Frequency of microsatellite instability in gynecologic cancers and the efficacy of immune checkpoint inhibitors treated: real-world data from a single gynecologic center</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kuang</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2958449/overview"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Jing</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2786005/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Tong</surname><given-names>Lingling</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qianqi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Huanxin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Min</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Dongni</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Cheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2778269/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Pathology, West China Second University Hospital of Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Kanjoormana Aryan Manu, Amala Cancer Research Centre, India</p></fn><fn fn-type="edited-by"><p>Reviewed by: Song Yizuo, First Affiliated Hospital of Wenzhou Medical University, China</p><p>Liubov A. Tashireva, Tomsk Cancer Research Institute (RAS), Russia</p></fn><corresp id="fn001">*Correspondence: Cheng Wang, <email xlink:href="mailto:hxeycc@126.com">hxeycc@126.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1567824</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Kuang, Zeng, Tong, Liu, Sun, Feng, Liang, Wang and Wang</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kuang, Zeng, Tong, Liu, Sun, Feng, Liang, Wang and Wang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objective</title><p>This study evaluated the incidence of Microsatellite Instability-High (MSI-H) in patients with gynecologic cancers in a single gynecologic center and investigated the effect of immune checkpoint inhibitors (ICIs) in treating MSI-H in advanced or recurrent gynecologic cancers.</p></sec><sec><title>Methods</title><p>We conducted a retrospective study of patients diagnosed with gynecological cancers between June 2021 and May 2024. We investigated their clinicopathological information, the results of microsatellite instability (MSI), the immunohistochemistry staining PD-L1 analyses, the molecular classification testing, and the tumor response to treatment with ICIs.</p></sec><sec><title>Results</title><p>Among 1333 patients included in the analysis, the frequency of MSI-H was 1.3% (3/223) in cervical cancer, 25.7% (280/1091) in endometrial cancer, and 10.5% (2/19) in ovarian or tubal and peritoneal cancer. When the patients were evaluated by histologic type, the frequency of MSI-H was 26.1% (241/921) in endometrioid adenocarcinoma and 35.1% (20/57) in mixed adenocarcinoma. Molecular classification results for the 1020 cases that successfully underwent the tests were 71 for the POLE mutation (POLEmut) subtype, 271 for MMR-deficiency (MMRd) subtype, 571 for the non-specific molecular profile (NSMP) subtype, and 107 for the p53 abnormality (p53abn) subtype. Thirty-five patients were treated with ICIs for at least one cycle. The objective response rate (ORR) was 34.3% (95% CI, 19.1% to 52.2%). Among the patients who achieved an objective response, the median time to respond was 2.65 months, and the median duration of response had not been reached. The median progression-free survival (PFS) was 9 months (95% CI, 4 to 10), and the median overall survival (OS) had not been reached. Additionally, in the patients with endometrial cancer, the median PFS in MSI-H patients was 5 months versus 3 months in microsatellite stable (MSS) patients (&#x00394; = 2 months; p=0.92), and the median OS in both MSI-H and MSS patients had not been reached (p=0.89).</p></sec><sec><title>Conclusion</title><p>This study had shown the MSI-H frequencies for the three major types of gynecological tumors and demonstrated the clinical benefit of treatment with ICIs in patients with advanced or recurrent gynecologic cancer. Among endometrial cancer patients, the effects of immunotherapy may be consistent regardless of MSI status.</p></sec></abstract><kwd-group><kwd>microsatellite instability</kwd><kwd>gynecologic cancers</kwd><kwd>immunotherapy</kwd><kwd>immune checkpoint inhibitors (ICIs)</kwd><kwd>objective response rate (ORR)</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This project was supported by the Medical Research Project of Sichuan Medical Association (Grant No. S2024032), the Key research and development project of cadre health care in Sichuan Province Research (Grant No. ZH2023-1701), and the New Sprout Fund of West China Second University Hospital of Sichuan University (Grant No. KX178).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="5"/><equation-count count="0"/><ref-count count="45"/><page-count count="11"/><word-count count="5187"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Immunity and Immunotherapy</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>In recent years, immune checkpoint inhibitors (ICIs) have undoubtedly been one of the successful tumor immunotherapies, and their rapid development has revolutionized oncology treatment, leading to a change in solid tumor therapy (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). However, immunotherapy offers new treatment options for patients with advanced/recurrent gynecological tumors compared to conventional therapies. Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors are ineffective or have a short efficacy duration in most patients due to primary or secondary resistance, a bottleneck for immunotherapy. Therefore, finding more effective molecular predictive markers would benefit the future development of immunotherapy. Microsatellite instability (MSI) status is now widely used as a screening tool to identify Lynch syndrome, which is associated with an increased risk of both endometrial and ovarian cancers (<xref rid="B3" ref-type="bibr">3</xref>) and as one of the predictive markers of efficacy in ICIs (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Normal cells can detect and repair base mismatches that arise during DNA replication and recombination, usually by the four common mismatch repair (MMR) proteins, MLH1, MSH2, MSH6, and PMS2 (<xref rid="B7" ref-type="bibr">7</xref>). When MMR genes are mutated, or the promoter of the MLH1 gene is methylated, it is possible to result in deficiency-MMR (dMMR) (<xref rid="B8" ref-type="bibr">8</xref>). Then, the dMMR can accumulate DNA replication errors, leading to microsatellite instability-high (MSI-H) (<xref rid="B9" ref-type="bibr">9</xref>). MSI-H/dMMR tumors share similar histopathological features, including somatic hypermutation, increased neoantigen formation, more lymphocytic infiltration, and strong expression of immune checkpoint proteins (e.g., PD-L1, PD-1). They correlate strongly with a high or low tumor mutational burden (TMB) degree. Neoantigens generated through MSI-H/dMMR may become targets for immunotherapy, activating the immune system through immune checkpoint inhibitors, which then modulate their anti-tumor effects (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).</p><p>MSI-H/dMMR is associated with multiple types of gynecologic malignancies. Among patients with gynecologic cancers, the frequency of endometrial cancer ranges from 20% to 40% (<xref rid="B12" ref-type="bibr">12</xref>), ovarian cancer from 1% to 3%, and cervical cancer from 2% to 4% (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>). The Food and Drug Administration (FDA) granted accelerated approval for Pembrolizumab in 2017 for treating a wide range of unresectable or metastatic MSI-H/dMMR solid tumors (<xref rid="B5" ref-type="bibr">5</xref>). Some follow-up studies have shown a high treatment response rate (<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). Recently, the National Medical Products Administration (NMPA) has successively approved several domestic PD-1/PD-L1 inhibitors, such as tislelizumab, for the pan-oncological MSI-H/dMMR indication. RATIONALE-209 is a single-arm, open-label, multi-center Phase II study to evaluate the efficacy and safety of tislelizumab monotherapy in patients with treated, locally advanced, unresectable, or metastatic MSI-H/dMMR solid tumors and is the first clinical study to publish subgroup data from a Chinese population-based MSI-H/dMMR gynecological tumor subgroup. The results showed that the objective response rate (ORR) of tislelizumab in MSI-H/dMMR gynecological tumors was 53.3%, including 46.2% in patients with endometrial cancer, and the efficacy of tislelizumab was assessed to be PR in patients with ovarian and cervical cancers (<xref rid="B19" ref-type="bibr">19</xref>). Particularly in endometrial cancer, about 20%-30% of patients have dMMR/MSI-H status, and these patients respond better to immunotherapy. For patients with proficient mismatch repair (pMMR)/microsatellite instability-stable (MSS), the efficacy of immunotherapy is unclear or controversial. A meta-analysis study showed that only combining anti-PD-1 agents with chemotherapy resulted in a PFS benefit in pMMR patients (<xref rid="B20" ref-type="bibr">20</xref>). Another meta-analysis showed that, when stratified by MMR status, patients with pMMR only had an improvement in PFS (HR=0.74) but did not reach statistical significance in OS (HR=0.86) (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Although immunotherapy is currently effective in randomized trials, results from retrospective immunotherapy studies in gynecological tumors are still limited. In this study, we retrospectively evaluated the incidence of MSI-H in patients with gynecologic cancers in our center and investigated the effect of ICIs in treating advanced or recurrent gynecologic cancers with MSI-H status. We also focused on the difference in efficacy for patients with advanced or recurrent endometrial cancer with MSS or MSI-H status.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2_1"><title>Study design and patients</title><p>We retrospectively summarized the medical records of patients with different gynecologic solid cancers who underwent MSI testing at the Second West China Hospital of Sichuan University between June 2021 and May 2024. A total of 1342 patients were tested for MSI, of which seven were excluded because no clinical information was available for questioning after the external consultation, 2 MSI tests failed due to DNA quality problems, and 1333 cases were successfully enrolled. We further reviewed the clinicopathological and radiological records of patients who were diagnosed with advanced/recurrent gynecological cancers and treated with at least one cycle of ICIs. The patient inclusion criteria are shown in a flow diagram in <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>. Patients receive tislelizumab/pembrolizumab 200 mg intravenously (IV) every 3 weeks until the condition worsens, an intolerable toxic reaction occurs, the physician makes a decision, or the patient withdraws consent. The study was approved by the Ethics Committee of West China Second University Hospital of Sichuan University Institutional [No.2024 (181)], and conducted according to Helsinki&#x02019;s Declaration.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Flow diagram of patient selection. MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSS, microsatellite stable; ICIs, immune checkpoint inhibitors; EC, Endometrial cancer; POLEmut, POLE mutation; MMRd, MMR deficiency; NSMP, non-specific molecular profile; p53abn, p53 abnormality.</p></caption><graphic xlink:href="fimmu-16-1567824-g001" position="float"/></fig></sec><sec id="s2_2"><title>Microsatellite instability testing</title><p>The UPure formalin-fixed paraffin-embedded (FFPE) Tissue DNA Kit (Biokeyston, Chengdu, China) was used to extract DNA from tissues with enriched tumor and non-tumor areas. Based on the recommendations in the Bethesda guidelines, the MSI testing kit (Tongshu, BioTech, Changzhou, China) with five markers (BAT25, BAT26, D2S123, D5S346, D17S250) was used to compare the microsatellite status of tumor and normal tissue DNA. MSI-H is defined as instability in &#x02265; 2 loci, low microsatellite instability (MSI-L) is defined as instability in one locus, and MSS is defined as no instability in the five loci. Two experienced molecular pathologists carried out the interpretation.</p></sec><sec id="s2_3"><title>Immunohistochemical analysis</title><p>The slides with four &#x000b5;m-thick tissue sections were stained with PD-L1 immunohistochemical 22C3 antibody (Agilent Technologies, Inc., Santa Clara, CA) and p53(clone MX056, Fuzhou Maxin, China) at our institution. The measure of PD-L1 expression was the combined positive score (CPS), defined as the ratio of PD-L1&#x02013;positive cells (tumor cells, lymphocytes, and macrophages) to the total number of tumor cells multiplied by 100. PD-L1 positivity was defined as a CPS of 1 or greater. Criteria for interpreting p53 immunostaining were used as described previously (<xref rid="B22" ref-type="bibr">22</xref>).</p></sec><sec id="s2_4"><title>Molecular classification testing</title><p>At our center, we used immunohistochemistry (IHC) for p53, MSI assay, and Sanger sequencing to detect pathogenic variants in the structural domain of the POLE exonuclease (primer sequences are available upon request) based on the Proactive molecular risk classifier for endometrial cancer (ProMisE) assay strategy. We classified the endometrial cancers into four distinct molecular subgroups: POLE mutation (POLEmut), MMR deficiency (MMRd), p53 abnormality (p53abn), or no specific molecular profile (NSMP) (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). MMR IHC and molecular testing for MSI are used to detect MMR defects. These two approaches have comparable sensitivity and are shown to be ~95% concordant (<xref rid="B25" ref-type="bibr">25</xref>). Therefore, we consider the results of the MSI assay and the MMR IHC equivalent if we treat the MSS/MSS-L as a pMMR and the MSI-H as a dMMR.</p></sec><sec id="s2_5"><title>Outcomes</title><p>Baseline tumor assessment before treatment initiation and response is assessed by abdominopelvic and/or chest computed tomography scans at least every 9 weeks. Response evaluation criteria in solid tumor (RECIST1.1) and immunotherapy-related RECIST (irRECIST) were utilized to evaluate tumor response (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). The primary endpoint was ORR, defined as the proportion of patients with complete response (CR) or partial response (PR). Secondary endpoints include time to response (TTR) and duration of response (DOR), the time from the first occurrence of CR or PR to disease progression or death, whichever occurs first. Progressive-free survival (PFS) is defined as the time from the first dose of ICI treatment to tumor progression or death, whichever occurs first. Overall survival (OS) is defined as the time from the first dose of ICI treatment to death from any cause. Efficacy and safety analyses included all patients who received at least one cycle of ICIs.</p></sec><sec id="s2_6"><title>Statistical analysis</title><p>Demographic and baseline characteristics and response measures were summarized using descriptive statistics or league tables. ORR point estimates were accompanied by 95% CIs using the Clopper-Pearson exact method based on the binomial distribution. Patients without response data were considered non-responders. The Kaplan-Meier method estimated the duration of response, PFS, and OS. All statistical analyses were performed using R software (version 4.2.1). A p-value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Patients and the frequency of MSI-H in gynecologic cancers</title><p>A total of 1335 patients with gynecologic cancers were included in the analysis. Due to insufficient DNA quality, 2 of the patient samples failed the MSI test. One patient underwent MSI testing twice because of two synchronous primary cancers. Patients were categorized into MSI-H and MSI-L/MSS based on MSI status to compare baseline clinicopathologic parameters. The specific results are shown in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S1</bold>
</xref>. Most patients (71.2%, 949/1333) were aged over 50 years; Endometrial/uterine cancer accounted for the highest proportion of cases included in this study, at 81.8% (1091/1333). This cancer type was also the highest in the MSI-H population, with a high percentage of 98.2% (280/285). The majority of patients (72.7%, 969/1333) were diagnosed with a tumor International Federation of Gynecology and Obstetrics (FIGO) stage I-II, and 74.9% (998/1333) had a tumor of G1/2.</p><p>By the origin of cancer, the frequency of MSI-H was 1.3% (3/223) in cervix/vulvar/vagina cancer, 25.7% (280/1091) in endometrial/uterine cancer, 10.5% in ovarian/peritoneal/tubal cancer (2/19) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2A</bold>
</xref>). Regardless of the origin of cancer not considered, when the patients were evaluated by histologic type, the frequency of MSI-H was 23.1% (6/26) in carcinosarcoma, 26.1% (240/920) in endometrioid adenocarcinoma, 35.1% (20/57) in mixed adenocarcinoma, 1.8% (1/54) in serous carcinoma, 1.9% (3/157) in squamous cell carcinoma, 52.9% (9/17) in dedifferentiated carcinoma which is the highest, and 18.5% (5/27) in clear cell carcinoma, but in other types such as adeno-squamous carcinoma, neuroendocrine carcinoma, etc. the frequency was only 1.3% (1/77) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2B</bold>
</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>The frequency of MSI-H in gynecologic cancers. <bold>(A)</bold> divided by different origins of cancers; <bold>(B)</bold> divided by different histologic types. MSI-H, microsatellite instability-high.</p></caption><graphic xlink:href="fimmu-16-1567824-g002" position="float"/></fig><p>Out of 1091 endometrial cancers, 1024 cases underwent molecular classification tests, of which 4 cases could not be typed due to failure of the POLE sequencing test. Molecular classification results were 71 for POLEmut, 271 for MMRd, 571 for NSMP, and 107 for P53abn among the 1020 successfully molecularly classified cases (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S2</bold>
</xref>).</p></sec><sec id="s3_2"><title>Baseline clinicopathologic characteristics of patients treated with ICIs</title><p>As shown in <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>, 35 patients were treated with at least one ICI, and 16 were treated after recurrence. Among them, the median age of patients was 54 [Inter Quartile Range (IQR), 48 to 58], and 82.9% (29/35) had FIGO stage III or FIGO stage IV disease at the initial diagnosis. In total, the most common type represented among the patients is cervical cancer (n=22), followed by endometrial cancer (n=11), and the remaining two cases were vulvar cancer. There were 31% (11/35) cases of MSI-H tumors. Others were in MSS status. Only 6 out of 11 endometrial cancers were analyzed for molecular classification. Only 1 case was the p53abn subtype, and the other five were the MMRd subtype. PD-L1 expression was assessed in 28 patients, 27 (96.4%) of whom were PD-L1 positive. The patients with MSS status were also treated with ICIs because their tumors expressed PD-L1 or their histology matched that of patients who responded to ICIs. The specific drugs of the ICIs used were pembrolizumab (22.9%, 8/35) and tislelizumab (77.1%, 27/35). As of 25 December 2024, the median follow-up was 17 months (1 to 56 months). Seventeen patients (48.6%) discontinued ICIs, most commonly due to disease progression or death. Patients received a median of 8 cycles of chemotherapy with ICIs (ranging from 1 to 29 cycles).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of patients treated with ICIs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Characteristic</th><th valign="middle" align="center" rowspan="1" colspan="1">n (%)</th></tr></thead><tbody><tr><th valign="middle" colspan="2" align="left" rowspan="1">Age</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Median (IQR)</td><td valign="middle" align="center" rowspan="1" colspan="1">54 (48-58)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Range</td><td valign="middle" align="center" rowspan="1" colspan="1">33-74</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">FIGO stage</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">I-II</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (17.1)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">III-IV</td><td valign="middle" align="center" rowspan="1" colspan="1">29 (82.9)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">Origin of cancer</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CC</td><td valign="middle" align="center" rowspan="1" colspan="1">22 (62.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">EC</td><td valign="middle" align="center" rowspan="1" colspan="1">11 (31.4)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VC</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (5.7)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">Histology</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Endocervical adenocarcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (5.7)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Carcinosarcoma</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Clear cell carcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Dedifferentiated carcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (5.7)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Endometrioid adenocarcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">7 (20)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">serous carcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.8)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Squamous cell carcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">21 (60)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">PD-L1 expression status</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Positive</td><td valign="middle" align="center" rowspan="1" colspan="1">27 (77.1)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Negative</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Unknown</td><td valign="middle" align="center" rowspan="1" colspan="1">7 (20)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">MSI status</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">MSI-H</td><td valign="middle" align="center" rowspan="1" colspan="1">11 (31.4)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">MSS</td><td valign="middle" align="center" rowspan="1" colspan="1">24 (68.6)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">Molecular classification*</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">POLEmut</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">MMRd</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (45.5)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSMP</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">p53abn</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (0.09)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" rowspan="1" colspan="1">5 (45.6)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">Previous radiotherapy</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">yes</td><td valign="middle" align="center" rowspan="1" colspan="1">32 (91.4)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">no</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (5.7)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Unknown</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.9)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">Previous antineoplastic agents</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Paclitaxel</td><td valign="middle" align="center" rowspan="1" colspan="1">35 (100)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Cisplatin</td><td valign="middle" align="center" rowspan="1" colspan="1">15 (42.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Carboplatin</td><td valign="middle" align="center" rowspan="1" colspan="1">23 (65.7)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Bevacizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">12 (34.2)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Oxaliplatin</td><td valign="middle" align="center" rowspan="1" colspan="1">4 (11.4)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gemcitabine</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.8)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Lenvatinib</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.8)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Nedaplatin</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (2.8)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">No. of previous lines of chemotherapy</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">1</td><td valign="middle" align="center" rowspan="1" colspan="1">17 (48.5)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">16 (45.7)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02265;3</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (5.7)</td></tr><tr><th valign="middle" colspan="2" align="left" rowspan="1">Type of immune checkpoint inhibitor</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">8 (22.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Tislelizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">27 (77.1)</td></tr></tbody></table><table-wrap-foot><fn><p>ICIs, immune checkpoint inhibitors; IQR, Inter Quartile Range; FIGO, International Federation of Gynecology and Obstetrics; CC, Cervical cancer; EC, Endometrial cancer; VC, Vulval cancer; PD-L1, programmed death-ligand 1; MSI-H, microsatellite high; MSS, microsatellite stable; POLEmut, POLE mutation; MMRd, MMR deficiency; NSMP, non-specific molecular profile; p53abn, p53 abnormality; NA, no available.</p></fn><fn><p>*Molecular classification testing is only available for Endometrial Cancer.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_3"><title>Antitumor activity</title><p>In the total population (n=35), five patients (14.3%) had a confirmed complete response, and 7 (20.0%) had a confirmed partial response, resulting in an ORR of 34.3% (95% CI, 19.1% to 52.2%) (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>). According to the origin of the tumor, the ORR was 40.9% for cervical cancer, 18.2% for endometrial cancer, and 50% for vulvar cancer (<xref rid="T3" ref-type="table">
<bold>Table&#x000a0;3</bold>
</xref>). Among patients with MSI-H tumors (n=11), the ORR was 36.4% (3 CRs and 1 PR). The ORRs were 25% (2/8) for endometrial cancer with MSI-H and 66.7% (2/3) for cervical cancer with MSI-H (<xref rid="T4" ref-type="table">
<bold>Table&#x000a0;4</bold>
</xref>). The ORR for patients treated with Pembrolizumab was 37.5% (3/8) compared to 33.3% (9/27) for patients treated with Tislelizumab (<xref rid="T5" ref-type="table">
<bold>Table&#x000a0;5</bold>
</xref>). Among the patients who achieved an objective response, the median time to response was 2.65 months (range, 0.8 to 7.0 months), the median duration of response had not been reached (range, 7 to 30+ months), and the 12-month DOR rate was 65.6% (95%CI, 32% to 85.5%) (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>).</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Tumor responses assessed by RECIST v.1.1 and irRECIST.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Antitumor activity</th><th valign="middle" align="left" rowspan="1" colspan="1">Total (n=35)</th><th valign="middle" align="left" rowspan="1" colspan="1">MSI-H (n=11)</th><th valign="middle" align="left" rowspan="1" colspan="1">MSS (n=24)</th></tr></thead><tbody><tr><th valign="middle" colspan="4" align="left" rowspan="1">Best overall response</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CR</td><td valign="middle" align="left" rowspan="1" colspan="1">5 (14.3)</td><td valign="middle" align="left" rowspan="1" colspan="1">3 (27.3)</td><td valign="middle" align="left" rowspan="1" colspan="1">2 (8.3)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PR</td><td valign="middle" align="left" rowspan="1" colspan="1">7 (20)</td><td valign="middle" align="left" rowspan="1" colspan="1">1 (9.1)</td><td valign="middle" align="left" rowspan="1" colspan="1">6 (25.0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SD</td><td valign="middle" align="left" rowspan="1" colspan="1">7 (20)</td><td valign="middle" align="left" rowspan="1" colspan="1">2 (18.2)</td><td valign="middle" align="left" rowspan="1" colspan="1">5 (20.8)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PD</td><td valign="middle" align="left" rowspan="1" colspan="1">10 (28.6)</td><td valign="middle" align="left" rowspan="1" colspan="1">3 (27.3)</td><td valign="middle" align="left" rowspan="1" colspan="1">7 (29.2)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Not able to be assessed*</td><td valign="middle" align="left" rowspan="1" colspan="1">6 (17.1)</td><td valign="middle" align="left" rowspan="1" colspan="1">2 (18.2)</td><td valign="middle" align="left" rowspan="1" colspan="1">4 (16.7)</td></tr><tr><th valign="middle" align="left" rowspan="1" colspan="1">ORR</th><th valign="middle" align="left" rowspan="1" colspan="1">12 (34.3)</th><th valign="middle" align="left" rowspan="1" colspan="1">4 (36.4)</th><th valign="middle" align="left" rowspan="1" colspan="1">8 (33.3)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">95%CI</td><td valign="middle" align="left" rowspan="1" colspan="1">19.1-52.2</td><td valign="middle" align="left" rowspan="1" colspan="1">10.9-69.2</td><td valign="middle" align="left" rowspan="1" colspan="1">15.6-55.3</td></tr><tr><th valign="middle" align="left" rowspan="1" colspan="1">DCR</th><th valign="middle" align="left" rowspan="1" colspan="1">19 (54.3)</th><th valign="middle" align="left" rowspan="1" colspan="1">6 (54.5)</th><th valign="middle" align="left" rowspan="1" colspan="1">13 (54.2)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">95%CI</td><td valign="middle" align="left" rowspan="1" colspan="1">36.6-71.2</td><td valign="middle" align="left" rowspan="1" colspan="1">23.4-83.3</td><td valign="middle" align="left" rowspan="1" colspan="1">32.8-74.4</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">TTR (mo)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Median(95%CI)</td><td valign="middle" align="left" rowspan="1" colspan="1">2.65 (1.7-4.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">2.85 (2.4-4)</td><td valign="middle" align="left" rowspan="1" colspan="1">2.2 (0.8-7.0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Range</td><td valign="middle" align="left" rowspan="1" colspan="1">0.8-7</td><td valign="middle" align="left" rowspan="1" colspan="1">2.4-4</td><td valign="middle" align="left" rowspan="1" colspan="1">0.8-7</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">DOR (mo)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Median</td><td valign="middle" align="left" rowspan="1" colspan="1">NR</td><td valign="middle" align="left" rowspan="1" colspan="1">NR</td><td valign="middle" align="left" rowspan="1" colspan="1">NR</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Range</td><td valign="middle" align="left" rowspan="1" colspan="1">7 to &#x02265;30</td><td valign="middle" align="left" rowspan="1" colspan="1">9 to &#x02265;30</td><td valign="middle" align="left" rowspan="1" colspan="1">7 to 14</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as No. (%) unless otherwise noted. RECIST, response evaluation criteria in solid tumors; irRECIST, immunotherapy related RECIST; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; TTR, time to response; DOR, duration of response; NR, not reached.</p></fn><fn><p>*Patients who had no postbaseline tumor assessment because of death, withdrawal of consent, loss to follow-up, or start of new anticancer therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Antitumor activity of ICIs with different origins of cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Origins of cancer</th><th valign="middle" align="center" rowspan="1" colspan="1">No.</th><th valign="middle" align="center" rowspan="1" colspan="1">CR, n (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">PR, n (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">ORR (%)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Cervical cancer</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (13.6)</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (27.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">40.9</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Endometrial cancer</td><td valign="middle" align="center" rowspan="1" colspan="1">11</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (18.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">18.2</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Vulvar cancer</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (50)</td><td valign="middle" align="center" rowspan="1" colspan="1">50</td></tr></tbody></table><table-wrap-foot><fn><p>ICIs, immune checkpoint inhibitors; CR, complete response; PR, partial response; ORR, objective response rate.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table&#x000a0;4</label><caption><p>Antitumor activity of ICIs in MSI-H cancers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Origins of cancer</th><th valign="middle" align="center" rowspan="1" colspan="1">No.</th><th valign="middle" align="center" rowspan="1" colspan="1">CR, n (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">PR, n (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">ORR (%)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Cervical cancer</td><td valign="middle" align="center" rowspan="1" colspan="1">3</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (33.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (33.3)</td><td valign="middle" align="center" rowspan="1" colspan="1">66.6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Endometrial cancer</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (25)</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">25.2</td></tr></tbody></table><table-wrap-foot><fn><p>ICIs, immune checkpoint inhibitors; MSI-H, microsatellite high; CR, complete response; PR, partial response; ORR, objective response rate.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table&#x000a0;5</label><caption><p>Antitumor activity of different types of ICIs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Type of ICIs</th><th valign="middle" align="center" rowspan="1" colspan="1">No.</th><th valign="middle" align="center" rowspan="1" colspan="1">CR, n (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">PR, n (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">ORR (%)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (25.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (12.5)</td><td valign="middle" align="center" rowspan="1" colspan="1">37.5</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Tislelizumab</td><td valign="middle" align="center" rowspan="1" colspan="1">27</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (11.1)</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (22.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">33.3</td></tr></tbody></table><table-wrap-foot><fn><p>ICIs, immune checkpoint inhibitors; CR, complete response; PR, partial response; ORR, objective response rate.</p></fn></table-wrap-foot></table-wrap><p>At the time of data cutoff, 21 (60%) patients in the total population had experienced disease progression or death. The median PFS was 9 months (95% CI, 4 to 10), and the estimated PFS rates at 6 and 12 months were 57.1% and 39.3%, respectively (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3A</bold>
</xref>). Seven patients (20.0%) in the total population had died. In the total population, the median OS had not been reached [95% CI, 8 to not evaluable (NE)] (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3B</bold>
</xref>). The OS rate at 12 months was 75.7% (95% CI, 58.8% to 92.6%). In the endometrial cancer group, the median PFS in MSI-H patients was 5 months versus 3 months in MSS patients (&#x00394; = 2 months, p=0.92) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3C</bold>
</xref>); the median OS in both MSI-H and MSS patients had not been NR (p=0.89) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3D</bold>
</xref>). When we focus on using different types of ICIs, the median PFS in the Tislelizumab group was 7 months. In contrast, the median PFS in the Pembrolizumab group had not been reached (p=0.09) (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4A</bold>
</xref>). The median OS in the Tislelizumab and Pembrolizumab groups had not been reached (p=0.54) (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4B</bold>
</xref>).</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Kaplan-Meier analysis of patients treated with ICIs(n=35). <bold>(A)</bold> PFS in the overall population and <bold>(B)</bold> OS in the overall population; <bold>(C)</bold> PFS in EC patients who were in MSI-H vs. MSS groups; and <bold>(D)</bold> OS in EC patients who were in MSI-H vs. MSS groups. Tick marks represent censored patients. NR, not reached; PFS, progression-free survival; OS, overall survival; MSI-H, microsatellite instability-high; MSS, microsatellite stable.</p></caption><graphic xlink:href="fimmu-16-1567824-g003" position="float"/></fig><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Kaplan-Meier analysis of patients treated with different types of ICIs. <bold>(A)</bold> PFS in patients who underwent Pembrolizumab vs. Tislelizumab groups; and <bold>(B)</bold> OS in patients who underwent Pembrolizumab vs. Tislelizumab groups. Tick marks represent censored patients. NR, not reached; PFS, progression-free survival; OS, overall survival.</p></caption><graphic xlink:href="fimmu-16-1567824-g004" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Using real-world data in an observational retrospective study, we summarized the frequency of MSI-H among patients with gynecological cancers in our single gynecologic center. Further, we analyzed patients with advanced or recurrent gynecological tumors receiving immunosuppressive therapy. We observed that the overall ORR was 34.3%, and 41.7% (5/12) of patients with an objective response had a complete response. Most importantly, tumor responses were durable; the median duration of response had not yet been reached. The OS outcomes were encouraging; the median OS time of patients with advanced or recurrent gynecological tumors treated with ICIs had not been reached, with an estimated 12-month OS rate of 75.7%.</p><p>After the FDA approval of pembrolizumab, an anti-PD-1 immune checkpoint monoclonal antibody, for the treatment of MSI-H/dMMR patients with unresectable or metastatic solid tumors in 2017, regardless of age and histological type (<xref rid="B20" ref-type="bibr">20</xref>). The exploration of MSI status as a predictive biomarker has been carried out in various tumor types. Thus, evaluating the MSI-H status in different types of solid tumors is vital. Large-scale analyses have shown a low incidence (3.5%-3.8%) of MSI-H in all the cancer types (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Our findings are in accord with recent studies that the frequency of MSI-H was 21.4%, and endometrial/uterine cancer has the highest MSI-H frequency, 25.7% among gynecologic cancers, while the frequency of MSI-H was 1.3% in cervical/vulvar/vagina cancer (<xref rid="B14" ref-type="bibr">14</xref>). In contrast, the frequency of ovarian/tubal/peritoneal cancers was 10.5% (2/19), higher than those reported in previous studies (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B28" ref-type="bibr">28</xref>). A possible explanation might be this study&#x02019;s small number of cases and the lack of focused pathological review. However, a previous study reported MSI-H rates of 7.9% and 13.2% for ovarian cancer, which used the two PCR-based MSI methods. This suggests that differences in MSI analysis methods may affect these results (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>When classified by histological type, the highest frequency of MSI-H was in dedifferentiated carcinomas, with 52.9%. There are similarities between the current study and ours in that half or more of dedifferentiated carcinomas lack mismatch repair proteins, and the percentage with deficiency ranges from 53% to 75% (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Dedifferentiated endometrial carcinoma is an uncommon and aggressive malignancy with a poor prognosis that is frequently misdiagnosed. Although its cause is usually unknown, it is thought to be related to Lynch syndrome (<xref rid="B32" ref-type="bibr">32</xref>). There is no data on the response rate of dedifferentiated cancers to ICIs, so the treatment of MSI-H/dMMR dedifferentiated cancers with ICIs may be considered. Contrary to earlier findings (<xref rid="B14" ref-type="bibr">14</xref>), which reported the frequency of MSI-H/dMMR in uterine carcinosarcoma was as low as 3.5%, the frequency of MSI-H was 23.1% (6/26) in carcinosarcoma in our study, which was relatively higher.</p><p>In other studies, the percentage of endometrial cancer molecular classification was found to be POLEmut (7.7%-12%), MMRd (28.1%-34.8%), p53abn (12.2%-23%), NSMP (32%-50.4%), respectively; compared to them, the results of endometrial cancer molecular typing in our center had a low percentage of POLEmut (6.9%), MMRd (26.6%), and P53abn (10.5%) were underrepresented, while NSMP (56%) was overrepresented (<xref rid="B33" ref-type="bibr">33</xref>&#x02013;<xref rid="B35" ref-type="bibr">35</xref>). As the six endometrial cancers that received immunotherapy had molecular classification results, and five were MMRd type, they met the recommendations of the National Comprehensive Cancer Network (NCCN) guidelines. They were sensitive to immunotherapy (pembrolizumab can be used in patients with advanced/MSI-H cancers) (<xref rid="B36" ref-type="bibr">36</xref>). We found a case of endometrial cancer with molecular typing of p53 aberrant subtype that was maintained in SD status after treatment with Pembrolizumab, still alive at the end of follow-up, with a follow-up time of 13 months. Typically, the p53abn subtype responds poorly to immunotherapy. One study showed an ORR of 13% for pembrolizumab in PD-L1-positive (including p53 mutant) endometrial cancer, but limited efficacy in the p53abn subgroup (<xref rid="B16" ref-type="bibr">16</xref>). However, immunotherapy (e.g., pembrolizumab) may be considered if MSI-H/dMMR or high TMB is present.</p><p>In the MSI-H/dMMR environment, the appearance of neoantigens is further increased, thereby activating immune activity in the body (<xref rid="B37" ref-type="bibr">37</xref>). Furthermore, CD8+ T cell activity was promoted, and apoptosis of tumor cells was further increased when PD-1 inhibitors were used in the MSI-H/dMMR tumor environment (<xref rid="B38" ref-type="bibr">38</xref>). The therapeutic value of PD-1/PD-L1 inhibitor monotherapy in MSI-H/dMMR has been confirmed in clinical trials and is currently being used in clinical practice. A meta-analysis of 14 studies, including 939 MSI-H cancer patients, reported a pooled ORR for ICI of 41.5% (95% CI, 34.9% to 48.4%) and a pooled DCR of 62.8% (95% CI, 34.9% to 48.4%). The pooled median PFS was 4.3 months (95% CI, 3.0 to 6.8), and the pooled median OS was 24 months (95% CI, 20.1 to 28.5) (<xref rid="B39" ref-type="bibr">39</xref>). However, the effectiveness of immunotherapy varies due to economic and medical conditions in different countries and regions. The Keynote-158 clinical trial showed the ORR for MSI-H patients in all tumor types was 34.3% (95% CI, 28.3% to 40.8%), 57.1% for endometrial, and 33.3% for ovarian cancers (<xref rid="B6" ref-type="bibr">6</xref>). In a Korean multi-center study, the ORR was 21.6% (8/37) for cervical cancer, 4.7% (2/43) for ovarian cancer, and 25.8% (8/31) for endometrial cancer (<xref rid="B15" ref-type="bibr">15</xref>). A recent study conducted in China has discovered that when evaluating Tislelizumab monotherapy in patients with MSI-H/dMMR solid tumors, the ORR was 53.3%, with an ORR of 46.2% (6/13) in patients with endometrial cancer and a DCR of 53.8% (7/13). One case of cervical cancer and one case of ovarian cancer both achieved PRs (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Although it is difficult to compare the results of this study with those of clinical trial studies, we observed that the ORR of MSI-H gynecological tumors did not differ significantly from that of the overall population, with an ORR for the total number of patients (n=35) of 34.3%. In contrast, the ORR for the MSI-H group (n=11) was 36.4% (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>). Then, we further focused on endometrial cancer, which has a high frequency of MSI-H. However, contrary to the finding of Marabelle, who reported a much higher ORR (57.1%) and longer median PFS (25.7 months) in MSI-H endometrial cancer (<xref rid="B6" ref-type="bibr">6</xref>), the ORR of MSI-H endometrial cancer in our study is 25.2%. Surprisingly, the high ORR (66.7%) was observed in cervical cancers with MSI-H status. We speculate this might be due to the low incidence of MSI-H in cervical cancers. Two of the only three cervical cancer patients with MSI-H who were treated with ICI reached ORR. Most importantly, our study found that the tumor response was durable: the median response duration had not been reached, consistent with previous studies (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Compared with some findings, our median PFS was longer, the median PFS of the total population is 9 months (95% CI, 4 to 10), probably because not all of our center&#x02019;s treatment regimens were immunosuppressive monotherapy regimens, and many patients received combination chemotherapy or targeted therapies, which resulted in slower disease progression (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B40" ref-type="bibr">40</xref>). A recent study has also found that the combination therapy of pembrolizumab and lenvatinib provides a favorable outcome for 37.2% (35/94) of patients with recurrent endometrial cancer. This provides a new combination therapy strategy for MSS tumors (<xref rid="B41" ref-type="bibr">41</xref>). Although two of the MSS endometrial cancer group already had a PD response, the median PFS and median OS were not statistically significant in the MSI-H endometrial cancer group compared to the MSS endometrial cancer group. An explanation for this might be that endometrial cancer patients with MSS in our study were treated with ICIs due to their PD-L1-positive status. In the NRG-GY018 trial, both the dMMR and pMMR subgroups showed a significant improvement in PFS (HR 0.30 and 0.54, respectively, p&#x0003c;0.001) (<xref rid="B42" ref-type="bibr">42</xref>). Yan&#x02019;s meta-analysis provides solid evidence to support the use of lenvatinib in combination with pembrolizumab in the treatment of endometrial cancer, especially in patients with pMMR/MSS status (<xref rid="B43" ref-type="bibr">43</xref>). Therefore, for patients with pMMR/MSS endometrial cancer, immunosuppressive agents in combination with targeted therapies (e.g., CDK4/6 inhibitors, anti-angiogenic agents) need to be explored to improve efficacy further.</p><p>Many studies have shown that both Tislelizumab and Pembrolizumab have similar efficacy in the immunotherapy of gynecological cancers (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). As in this study, the ORR for patients treated with Pembrolizumab and Tislelizumab was identical (37.5% vs. 33.3%), and the median PFS and median OS were not statistically significant between the two groups. Pembrolizumab is generally used in patients with PD-L1 positivity (CPS&#x0003e;1) or MSI-H/dMMR in Cervical Cancer (<xref rid="B17" ref-type="bibr">17</xref>). In contrast, Tislelizumab may be suitable for patients with high PD-L1 expression (CPS&#x02265;10) or those more sensitive to immunotoxicity in cervical cancer (<xref rid="B19" ref-type="bibr">19</xref>). However, due to the lack of head-to-head trials, there are some limitations in directly comparing the efficacy of the two based on the available clinical trial data.</p><p>To our knowledge, this study is a retrospective study of a relatively large cohort in a western China single gynecologic center to evaluate the frequency of MSI-H in various gynecological tumor types and the therapeutic use of ICIs in gynecological cancers. The incidence of MSI-H in our center was comparable to that reported in most studies, and the ORR of gynecological tumors for immunotherapy was moderately high, with a long duration of DOR and a prolonged median PFS, revealing a significant clinical benefit of ICIs for gynecological tumors. This study has important implications for immunotherapy to advanced/recurrent gynecological cancers, especially in EC; ICIs can be attempted as a second-line treatment even if the MSI test is MSS. Our study has some limitations; as a real-world single-center retrospective study, there are missing and unknown data issues, and potential confounders and biases were introduced. For example, there were no ovarian cancer patients and only two vulvar cancer patients who received immunotherapy. Most of the patients who received immunotherapy were due to PD-L1 positivity, and the sample size of MSS endometrial cancer patients who received immunotherapy was small. However, real-world studies on immunotherapy in gynecological tumors are scarce, especially comparing MSI status in endometrial cancer. Therefore, our future studies will expand the sample size through multicenter collaborations to improve the findings&#x02019; statistical significance and clinical applicability and explore the discovery of other biomarkers predictive of ICIs in treating gynecological cancers. In addition, the predictive value of molecular classification types such as TP53 and POLE mutations for endometrial cancer treatment response remains to be clarified. There is also a need for further optimization of combination therapy strategies (e.g., immunotherapy + anti-vascular therapy + PARP inhibitors) for patients with MSS.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>This study has shown high MSI-H frequencies for the three major types of gynecological cancers, the highest of which is endometrial. Our study demonstrates the clinical benefit of treatment with ICIs in patients with advanced or recurrent gynecologic cancer. In patients with endometrial cancer, the effects of immunotherapy are likely to be consistent between the MSI-H and MSS status.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author/s.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by the Ethics Committee of West China Second University Hospital of Sichuan University Institutional. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants&#x02019; legal guardians/next of kin because That the medical records or biospecimens used in this study were obtained from previous clinical consultations, that the privacy and personally identifiable information of the research participants were protected, and that the waiver of informed consent would not adversely affect the rights and health of the research participants.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>WK: Visualization, Conceptualization, Data curation, Methodology, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. JZ: Formal analysis, Project administration, Supervision, Writing &#x02013; review &#x00026; editing. LT: Data curation, Formal analysis, Investigation, Writing &#x02013; original draft. QL: Investigation, Methodology, Resources, Validation, Writing &#x02013; original draft. HS: Data curation, Resources, Supervision, Writing &#x02013; original draft. MF: Formal analysis, Methodology, Writing &#x02013; original draft. DL: Methodology, Resources, Validation, Writing &#x02013; review &#x00026; editing. WW: Funding acquisition, Resources, Writing &#x02013; review &#x00026; editing. CW: Funding acquisition, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted without any commercial or financial relationships that could potentially create a conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s13"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567824/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567824/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Table1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pardoll</surname><given-names>DM</given-names></name></person-group>. <article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title>. <source>Nat Rev Cancer</source>. (<year>2012</year>) <volume>12</volume>:<page-range>252&#x02013;64</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrc3239</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Baas</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>D-W</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>P&#x000e9;rez-Gracia</surname><given-names>JL</given-names></name><name><surname>Han</surname><given-names>J-Y</given-names></name><etal/></person-group>. <article-title>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</article-title>. <source>Lancet</source>. (<year>2016</year>) <volume>387</volume>:<page-range>1540&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(15)01281-7</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moreira</surname><given-names>L</given-names></name><name><surname>Balaguer</surname><given-names>F</given-names></name><name><surname>Lindor</surname><given-names>N</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Identification of Lynch syndrome among patients with colorectal cancer</article-title>. <source>JAMA</source>. (<year>2012</year>) <volume>308</volume>:<page-range>1555&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jama.2012.13088</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Durham</surname><given-names>JN</given-names></name><name><surname>Smith</surname><given-names>KN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Aulakh</surname><given-names>LK</given-names></name><etal/></person-group>. <article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title>. <source>Science</source>. (<year>2017</year>) <volume>357</volume>:<page-range>409&#x02013;13</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcus</surname><given-names>L</given-names></name><name><surname>Lemery</surname><given-names>SJ</given-names></name><name><surname>Keegan</surname><given-names>P</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name></person-group>. <article-title>FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors</article-title>. <source>Clin Cancer Res</source>. (<year>2019</year>) <volume>25</volume>:<page-range>3753&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-4070</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Di Giacomo</surname><given-names>AM</given-names></name><name><surname>De Jesus-Acosta</surname><given-names>A</given-names></name><name><surname>Delord</surname><given-names>J-P</given-names></name><etal/></person-group>. <article-title>Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study</article-title>. <source>J Clin Oncol</source>. (<year>2020</year>) <volume>38</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/JCO.19.02105</pub-id>
<pub-id pub-id-type="pmid">31682550</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>G-M</given-names></name></person-group>. <article-title>Mechanisms and functions of DNA mismatch repair</article-title>. <source>Cell Res</source>. (<year>2008</year>) <volume>18</volume>:<fpage>85</fpage>&#x02013;<lpage>98</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cr.2007.115</pub-id>
<pub-id pub-id-type="pmid">18157157</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Genschel</surname><given-names>J</given-names></name><name><surname>Littman</surname><given-names>SJ</given-names></name><name><surname>Drummond</surname><given-names>JT</given-names></name><name><surname>Modrich</surname><given-names>P</given-names></name></person-group>. <article-title>Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha</article-title>. <source>J Biol Chem</source>. (<year>1998</year>) <volume>273</volume>:<page-range>19895&#x02013;901</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.273.31.19895</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leong</surname><given-names>V</given-names></name><name><surname>Lorenowicz</surname><given-names>J</given-names></name><name><surname>Kozij</surname><given-names>N</given-names></name><name><surname>Guarn&#x000e9;</surname><given-names>A</given-names></name></person-group>. <article-title>Nuclear import of human MLH1, PMS2, and MutLalpha: redundancy is the key</article-title>. <source>Mol Carcinog</source>. (<year>2009</year>) <volume>48</volume>:<page-range>742&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/mc.20514</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>795972</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.795972</pub-id>
<pub-id pub-id-type="pmid">35371084</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Uram</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title>. <source>N Engl J Med</source>. (<year>2015</year>) <volume>372</volume>:<page-range>2509&#x02013;20</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Backes</surname><given-names>FJ</given-names></name><name><surname>Haag</surname><given-names>J</given-names></name><name><surname>Cosgrove</surname><given-names>CM</given-names></name><name><surname>Suarez</surname><given-names>A</given-names></name><name><surname>Cohn</surname><given-names>DE</given-names></name><name><surname>Goodfellow</surname><given-names>PJ</given-names></name></person-group>. <article-title>Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker</article-title>. <source>Cancer</source>. (<year>2019</year>) <volume>125</volume>:<fpage>398</fpage>&#x02013;<lpage>405</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/cncr.31901</pub-id>
<pub-id pub-id-type="pmid">30561762</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cortes-Ciriano</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>W-Y</given-names></name><name><surname>Kim</surname><given-names>T-M</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name></person-group>. <article-title>A molecular portrait of microsatellite instability across multiple cancers</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<elocation-id>15180</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ncomms15180</pub-id>
<pub-id pub-id-type="pmid">28585546</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonneville</surname><given-names>R</given-names></name><name><surname>Krook</surname><given-names>MA</given-names></name><name><surname>Kautto</surname><given-names>EA</given-names></name><name><surname>Miya</surname><given-names>J</given-names></name><name><surname>Wing</surname><given-names>MR</given-names></name><name><surname>Chen</surname><given-names>H-Z</given-names></name><etal/></person-group>. <article-title>Landscape of microsatellite instability across 39 cancer types</article-title>. <source>JCO Precis Oncol</source>. (<year>2017</year>) <volume>2017</volume>:<elocation-id>PO.17.00073</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/PO.17.00073</pub-id>
<pub-id pub-id-type="pmid">29850653</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noh</surname><given-names>JJ</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Choi</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>J-W</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Frequency of mismatch repair deficiency/high microsatellite instability and its role as a predictive biomarker of response to immune checkpoint inhibitors in gynecologic cancers</article-title>. <source>Cancer Res Treat</source>. (<year>2022</year>) <volume>54</volume>:<page-range>1200&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4143/crt.2021.828</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Bang</surname><given-names>Y-J</given-names></name><name><surname>Berton-Rigaud</surname><given-names>D</given-names></name><name><surname>Elez</surname><given-names>E</given-names></name><name><surname>Pishvaian</surname><given-names>MJ</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><etal/></person-group>. <article-title>Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study</article-title>. <source>J Clin Oncol</source>. (<year>2017</year>) <volume>35</volume>:<page-range>2535&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/JCO.2017.72.5952</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Ros</surname><given-names>W</given-names></name><name><surname>Delord</surname><given-names>J-P</given-names></name><name><surname>Perets</surname><given-names>R</given-names></name><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study</article-title>. <source>J Clin Oncol</source>. (<year>2019</year>) <volume>37</volume>:<page-range>1470&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/JCO.18.01265</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frenel</surname><given-names>J-S</given-names></name><name><surname>Le Tourneau</surname><given-names>C</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>B</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Piha-Paul</surname><given-names>SA</given-names></name><name><surname>Gomez-Roca</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase ib KEYNOTE-028 trial</article-title>. <source>J Clin Oncol</source>. (<year>2017</year>) <volume>35</volume>:<page-range>4035&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/JCO.2017.74.5471</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zang</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors</article-title>. <source>Chin J Cancer Res</source>. (<year>2024</year>) <volume>36</volume>:<page-range>257&#x02013;69</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.21147/j.issn.1000-9604.2024.03.03</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartoletti</surname><given-names>M</given-names></name><name><surname>Montico</surname><given-names>M</given-names></name><name><surname>Lorusso</surname><given-names>D</given-names></name><name><surname>Mazzeo</surname><given-names>R</given-names></name><name><surname>Oaknin</surname><given-names>A</given-names></name><name><surname>Musacchio</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis</article-title>. <source>Cancer Treat Rev</source>. (<year>2024</year>) <volume>125</volume>:<elocation-id>102701</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ctrv.2024.102701</pub-id>
<pub-id pub-id-type="pmid">38422895</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>EY</given-names></name><name><surname>Kim</surname><given-names>ET</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Tan</surname><given-names>DSP</given-names></name><etal/></person-group>. <article-title>Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis</article-title>. <source>Gynecol Oncol</source>. (<year>2024</year>) <volume>187</volume>:<fpage>85</fpage>&#x02013;<lpage>91</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ygyno.2024.05.006</pub-id>
<pub-id pub-id-type="pmid">38735144</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Piskorz</surname><given-names>AM</given-names></name><name><surname>Bosse</surname><given-names>T</given-names></name><name><surname>Jimenez-Linan</surname><given-names>M</given-names></name><name><surname>Rous</surname><given-names>B</given-names></name><name><surname>Brenton</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies</article-title>. <source>J Pathol</source>. (<year>2020</year>) <volume>250</volume>:<page-range>336&#x02013;45</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/path.5375</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Casey</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group>. <article-title>POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting</article-title>. <source>Int J Gynecol Pathol</source>. (<year>2021</year>) <volume>40</volume>:<fpage>5</fpage>&#x02013;<lpage>16</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/PGP.0000000000000710</pub-id>
<pub-id pub-id-type="pmid">33290350</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corr</surname><given-names>B</given-names></name><name><surname>Cosgrove</surname><given-names>C</given-names></name><name><surname>Spinosa</surname><given-names>D</given-names></name><name><surname>Guntupalli</surname><given-names>S</given-names></name></person-group>. <article-title>Endometrial cancer: molecular classification and future treatments</article-title>. <source>BMJ Med</source>. (<year>2022</year>) <volume>1</volume>:<elocation-id>e000152</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmjmed-2022-000152</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stelloo</surname><given-names>E</given-names></name><name><surname>Jansen</surname><given-names>AML</given-names></name><name><surname>Osse</surname><given-names>EM</given-names></name><name><surname>Nout</surname><given-names>RA</given-names></name><name><surname>Creutzberg</surname><given-names>CL</given-names></name><name><surname>Ruano</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Practical guidance for mismatch repair-deficiency testing in endometrial cancer</article-title>. <source>Ann Oncol</source>. (<year>2017</year>) <volume>28</volume>:<fpage>96</fpage>&#x02013;<lpage>102</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/annonc/mdw542</pub-id>
<pub-id pub-id-type="pmid">27742654</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Sargent</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source>. (<year>2009</year>) <volume>45</volume>:<page-range>228&#x02013;47</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seymour</surname><given-names>L</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Perrone</surname><given-names>A</given-names></name><name><surname>Ford</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Mandrekar</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics</article-title>. <source>Lancet Oncol</source>. (<year>2017</year>) <volume>18</volume>:<page-range>e143&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30074-8</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hause</surname><given-names>RJ</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Salipante</surname><given-names>SJ</given-names></name></person-group>. <article-title>Classification and characterization of microsatellite instability across 18 cancer types</article-title>. <source>Nat Med</source>. (<year>2016</year>) <volume>22</volume>:<page-range>1342&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nm.4191</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MA</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name></person-group>. <article-title>Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America</article-title>. <source>Int J Cancer</source>. (<year>2011</year>) <volume>129</volume>:<page-range>1914&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/ijc.25835</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ono</surname><given-names>R</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Ishibashi</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Dedifferentiated endometrial carcinoma could be A target for immune checkpoint inhibitors (Anti PD-1/PD-L1 antibodies)</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>:<elocation-id>3744</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms20153744</pub-id>
<pub-id pub-id-type="pmid">31370215</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karnezis</surname><given-names>AN</given-names></name><name><surname>Hoang</surname><given-names>LN</given-names></name><name><surname>Coatham</surname><given-names>M</given-names></name><name><surname>Ravn</surname><given-names>S</given-names></name><name><surname>Almadani</surname><given-names>N</given-names></name><name><surname>Tessier-Cloutier</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas</article-title>. <source>Mod Pathol</source>. (<year>2016</year>) <volume>29</volume>:<page-range>302&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/modpathol.2015.155</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murali</surname><given-names>R</given-names></name><name><surname>Davidson</surname><given-names>B</given-names></name><name><surname>Fadare</surname><given-names>O</given-names></name><name><surname>Carlson</surname><given-names>JA</given-names></name><name><surname>Crum</surname><given-names>CP</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations</article-title>. <source>Int J Gynecol Pathol</source>. (<year>2019</year>) <volume>38 Suppl 1</volume>:<page-range>S40&#x02013;63</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/PGP.0000000000000491</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le&#x000f3;n-Castillo</surname><given-names>A</given-names></name><name><surname>de Boer</surname><given-names>SM</given-names></name><name><surname>Powell</surname><given-names>ME</given-names></name><name><surname>Mileshkin</surname><given-names>LR</given-names></name><name><surname>Mackay</surname><given-names>HJ</given-names></name><name><surname>Leary</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy</article-title>. <source>J Clin Oncol</source>. (<year>2020</year>) <volume>38</volume>:<page-range>3388&#x02013;97</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/JCO.20.00549</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talhouk</surname><given-names>A</given-names></name><name><surname>McConechy</surname><given-names>MK</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Li-Chang</surname><given-names>HH</given-names></name><name><surname>Kwon</surname><given-names>JS</given-names></name><name><surname>Melnyk</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>A clinically applicable molecular-based classification for endometrial cancers</article-title>. <source>Br J Cancer</source>. (<year>2015</year>) <volume>113</volume>:<fpage>299</fpage>&#x02013;<lpage>310</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/bjc.2015.190</pub-id>
<pub-id pub-id-type="pmid">26172027</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kommoss</surname><given-names>S</given-names></name><name><surname>McConechy</surname><given-names>MK</given-names></name><name><surname>Kommoss</surname><given-names>F</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Bunz</surname><given-names>A</given-names></name><name><surname>Magrill</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series</article-title>. <source>Ann Oncol</source>. (<year>2018</year>) <volume>29</volume>:<page-range>1180&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/annonc/mdy058</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abu-Rustum</surname><given-names>N</given-names></name><name><surname>Yashar</surname><given-names>C</given-names></name><name><surname>Arend</surname><given-names>R</given-names></name><name><surname>Barber</surname><given-names>E</given-names></name><name><surname>Bradley</surname><given-names>K</given-names></name><name><surname>Brooks</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology</article-title>. <source>J Natl Compr Canc Netw</source>. (<year>2023</year>) <volume>21</volume>:<fpage>181</fpage>&#x02013;<lpage>209</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.6004/jnccn.2023.0006</pub-id>
<pub-id pub-id-type="pmid">36791750</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors</article-title>. <source>Mol Cancer</source>. (<year>2018</year>) <volume>17</volume>:<elocation-id>129</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12943-018-0864-3</pub-id>
<pub-id pub-id-type="pmid">30139382</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Zhen</surname><given-names>Y-H</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells</article-title>. <source>Onco Targets Ther</source>. (<year>2017</year>) <volume>10</volume>:<page-range>3453&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/OTT.S130131</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrelli</surname><given-names>F</given-names></name><name><surname>Ghidini</surname><given-names>M</given-names></name><name><surname>Ghidini</surname><given-names>A</given-names></name><name><surname>Tomasello</surname><given-names>G</given-names></name></person-group>. <article-title>Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: A systematic review and meta-analysis</article-title>. <source>JAMA Oncol</source>. (<year>2020</year>) <volume>6</volume>:<page-range>1068&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/jamaoncol.2020.1046</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bogani</surname><given-names>G</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Powell</surname><given-names>MA</given-names></name><name><surname>Westin</surname><given-names>SN</given-names></name><name><surname>Slomovitz</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>KN</given-names></name><etal/></person-group>. <article-title>Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer</article-title>. <source>Ann Oncol</source>. (<year>2024</year>) <volume>35</volume>:<page-range>414&#x02013;28</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.annonc.2024.02.006</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Makker</surname><given-names>V</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Casado Herr&#x000e1;ez</surname><given-names>A</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Mackay</surname><given-names>H</given-names></name><name><surname>Santin</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775</article-title>. <source>J Clin Oncol</source>. (<year>2023</year>) <volume>41</volume>:<page-range>2904&#x02013;10</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/JCO.22.02152</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eskander</surname><given-names>RN</given-names></name><name><surname>Sill</surname><given-names>MW</given-names></name><name><surname>Beffa</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>RG</given-names></name><name><surname>Hope</surname><given-names>JM</given-names></name><name><surname>Musa</surname><given-names>FB</given-names></name><etal/></person-group>. <article-title>Pembrolizumab plus chemotherapy in advanced endometrial cancer</article-title>. <source>N Engl J Med</source>. (<year>2023</year>) <volume>388</volume>:<page-range>2159&#x02013;70</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMoa2302312</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ban</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1404669</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1404669</pub-id>
<pub-id pub-id-type="pmid">39185408</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matulonis</surname><given-names>UA</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name><surname>Santin</surname><given-names>AD</given-names></name><name><surname>Lisyanskaya</surname><given-names>AS</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study</article-title>. <source>Ann Oncol</source>. (<year>2019</year>) <volume>30</volume>:<page-range>1080&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/annonc/mdz135</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>F-F</given-names></name><name><surname>Zhang</surname><given-names>X-L</given-names></name><name><surname>Chen</surname><given-names>J-L</given-names></name><name><surname>Zhang</surname><given-names>T-T</given-names></name><name><surname>Sui</surname><given-names>X-C</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Tislelizumab combined with carboplatin-paclitaxel for treatment of metastatic or recurrent endometrial cancer: a retrospective clinical study</article-title>. <source>Clin Lab</source>. (<year>2022</year>) <volume>68</volume>(<issue>11</issue>). doi:&#x000a0;<pub-id pub-id-type="doi">10.7754/Clin.Lab.2022.211221</pub-id>
</mixed-citation></ref></ref-list></back></article>